MetaCap

Enact (ACT) vs Ryan Specialty (RYAN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enact (ACT) has outperformed Ryan Specialty (RYAN) over the past year, gaining 14.8% versus a loss of 17.8%. Over five years, ACT leads with a +106.4% price change compared with +17.5% for RYAN. Ryan Specialty is the larger company by market cap ($11.93 billion vs $5.94 billion), about 2.0 times the size.

On valuation, Enact trades at a lower forward P/E (8.8x vs 19.4x for Ryan Specialty). Enact offers the higher dividend yield (2.04% vs 1.08%). Enact converts more of its revenue into profit, with a net margin of 54.6% versus 2.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACT+14.78%RYAN-17.83%
+34%-9%-53%
Nov 21, 20251 yearNov 20, 2026
ACT+91.92%RYAN+17.90%
+124%+47%-30%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACT versus RYAN key metrics
MetricACTRYAN
Share price$44.18$47.09
Market cap$5.94B$11.93B
1-day change-0.02%+1.01%
YTD return+11.45%-8.79%
1-year return+14.78%-17.83%
5-year return+106.45%+17.46%
P/E ratio (TTM)9.2258.86
Forward P/E8.8219.38
EPS (TTM)$4.79$0.80
Dividend yield2.04%1.08%
Annual dividend$0.90$0.51
Revenue (latest FY)$1.24B$3.05B
Revenue growth (YoY)+2.83%+21.28%
Net income (latest FY)$674.24M$63.40M
Operating margin—16.18%
Net margin54.56%2.08%
52-week high$50.56$58.91
52-week low$37.03$29.28
Distance from 52-week high-12.62%-20.06%
Analyst consensusholdbuy
Avg. price target upside+6.38%+5.31%
Average volume422.78K1.98M
Shares outstanding134.44M119.69M
Employees4196,129
SectorFinanceFinance
IndustrySpecialty InsurersSpecialty Insurers

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Ryan Specialty is about 2.0 times larger than Enact by market value ($11.93B vs $5.94B).
  • ACT has outperformed RYAN by 32.6 percentage points over the past year.
  • Ryan Specialty trades at a higher earnings multiple (58.9x vs 9.2x trailing P/E).
  • Enact is more profitable, keeping 54.6 cents of every revenue dollar as net income versus 2.1 cents for Ryan Specialty.
  • Ryan Specialty grew revenue faster in its latest fiscal year (+21.28% vs +2.83%).

About Enact

ACT stock →

Enact Holdings, Inc. operates as a private mortgage insurance company in the United States.

Finance · Specialty Insurers · 419 employees

About Ryan Specialty

RYAN stock →

Ryan Specialty Holdings, Inc. operates as a service provider of specialty products and solutions for insurance brokers, agents, and carriers in the United States, Canada, the United Kingdom, rest of Europe, India, Singapore, and internationally.

Finance · Specialty Insurers · 6,129 employees

ACT vs RYAN FAQ

Which is bigger, Enact or Ryan Specialty?

Ryan Specialty (RYAN) is larger, with a market capitalization of $11.93B compared with $5.94B for Enact (ACT).

Which stock has performed better over the past year, ACT or RYAN?

ACT returned +14.78% over the past 12 months, compared with -17.83% for RYAN (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ACT or RYAN?

ACT has the lower trailing P/E at 9.2, versus 58.9 for RYAN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Enact or Ryan Specialty?

Enact has the higher yield at 2.04%, compared with 1.08% for Ryan Specialty.

Are Enact and Ryan Specialty in the same industry?

Yes. Both are classified in the Specialty Insurers industry within the Finance sector.

More comparisons